Ian Clark Sells 6,876 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) Director Ian Clark sold 6,876 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $106.90, for a total transaction of $735,044.40. Following the sale, the director owned 2,975 shares in the company, valued at $318,027.50. The trade was a 69.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Guardant Health Stock Up 0.8%

GH traded up $0.94 on Friday, hitting $118.95. The company’s stock had a trading volume of 2,633,856 shares, compared to its average volume of 2,090,416. Guardant Health, Inc. has a 12 month low of $36.36 and a 12 month high of $121.01. The firm has a market cap of $15.77 billion, a P/E ratio of -35.09 and a beta of 1.48. The company’s 50 day simple moving average is $90.53 and its 200-day simple moving average is $98.79.

Guardant Health (NASDAQ:GH) last issued its earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The business had revenue of $281.27 million for the quarter, compared to analyst estimates of $269.74 million. Guardant Health’s revenue for the quarter was up 39.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.62) earnings per share. Equities analysts predict that Guardant Health, Inc. will post -2.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a research note on Tuesday, April 21st. TD Cowen restated a “buy” rating on shares of Guardant Health in a research note on Thursday. JPMorgan Chase & Co. lifted their target price on Guardant Health from $130.00 to $135.00 and gave the company an “overweight” rating in a report on Friday, May 8th. UBS Group reiterated a “buy” rating and set a $175.00 price target on shares of Guardant Health in a research report on Friday, January 30th. Finally, Robert W. Baird initiated coverage on shares of Guardant Health in a report on Tuesday, February 17th. They issued an “outperform” rating and a $120.00 price target on the stock. Nineteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $129.00.

Institutional Investors Weigh In On Guardant Health

A number of institutional investors and hedge funds have recently made changes to their positions in the business. V Square Quantitative Management LLC bought a new stake in Guardant Health during the fourth quarter valued at $27,000. Chesapeake Asset Management LLC bought a new position in Guardant Health in the 4th quarter worth about $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Guardant Health in the 4th quarter valued at about $31,000. Elyxium Wealth LLC purchased a new stake in shares of Guardant Health in the 4th quarter valued at about $35,000. Finally, Parallel Advisors LLC boosted its position in shares of Guardant Health by 164.7% during the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after acquiring an additional 219 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.